In a significant blow to American biomedical research, renowned cancer scientist Dr. Feng Gensheng has left the United States and relocated to China, citing diminishing federal support for cancer research and an increasingly hostile scientific environment. His departure underscores growing concerns among researchers and policymakers that the U.S. is losing its edge in scientific innovation due to political decisions that have slashed research funding and driven top talent overseas.
Dr. Feng, a highly respected figure in tumor immunology, had been leading promising research at a major U.S. research university. Over the last decade, his work contributed to the development of novel immunotherapy strategies that showed early success in clinical trials. Many in the cancer research community saw him as a rising star — someone who could help shape the next generation of cancer treatment.
But the trajectory of his career in the U.S. took a turn this year when sweeping cuts to the federal science budget were implemented. Under directives pushed through during the Trump administration’s second term, funding for the National Cancer Institute and other key health research agencies was significantly reduced. The cuts, totaling billions of dollars, led to halted projects, staff layoffs, and the abrupt end of long-term studies. Dr. Feng’s own lab saw its core grant suspended, putting years of work at risk.
In an internal letter to colleagues before his departure, Dr. Feng reportedly expressed deep frustration over the instability of the research climate in the United States. He noted that while scientific progress requires long-term investment and institutional support, he increasingly found himself navigating uncertainty, bureaucratic obstacles, and a growing sense that science was being politicized.
“Science cannot thrive in an environment where support comes and goes with election cycles,” the letter read. “Research is a commitment not just to discovery, but to the people who dedicate their lives to it. That commitment has been broken.”
Dr. Feng’s move is not an isolated case. Over the past few years, an increasing number of American-based scientists — particularly those of international origin — have sought opportunities elsewhere. Many cite both the unpredictable funding environment and a perceived erosion of academic freedom. For researchers of Chinese descent, this trend has been accelerated by a climate of suspicion that emerged during Trump’s first term, when a series of investigations into academic espionage disproportionately targeted Chinese scientists, leading to dismissals, visa revocations, and public scrutiny, often without charges being filed.
Meanwhile, China has launched an aggressive campaign to attract global scientific talent. The country’s investments in research and development have surged, with significant funding earmarked for biotechnology, oncology, and artificial intelligence. In exchange for returning home, scientists like Dr. Feng are offered state-of-the-art laboratories, generous grants, and leadership roles in prestigious national institutes.
For Dr. Feng, the decision to move was as much about returning to his roots as it was about pursuing scientific freedom. In China, he is now leading a new oncology research center affiliated with one of the country’s top medical universities. The center is focused on precision immunotherapy and personalized cancer treatment — areas he had previously worked on in the U.S. but found increasingly difficult to fund.
The impact of his departure is already being felt in the American scientific community. Graduate students and postdoctoral fellows who had trained under him are now scrambling to find new mentors or funding to continue their work. Several of his collaborators have warned that ongoing clinical trials could face delays or cancellation due to the leadership vacuum.
More broadly, Dr. Feng’s exit highlights a critical issue facing the United States: the gradual erosion of its position as a global leader in science and technology. For decades, the U.S. has attracted the best minds from around the world, offering unmatched infrastructure, academic freedom, and a culture of innovation. But with rising political interference, shrinking research budgets, and tightening immigration policies, that reputation is increasingly under threat.
Industry leaders, academic institutions, and research advocates have sounded the alarm, urging the federal government to reconsider its approach. Many argue that science is a long-term investment with far-reaching benefits — from healthcare breakthroughs to economic growth — and that undermining it for short-term political gain will have lasting consequences.
While efforts are underway in Congress to restore some of the lost funding, the damage may already be done. The departure of scientists like Dr. Feng sends a powerful message to young researchers: that their futures may be brighter elsewhere. It also signals to other nations that the U.S., once the uncontested leader in science, is faltering.
As Dr. Feng settles into his new role in China, his story serves as both a warning and a reflection of shifting global dynamics. Scientific talent is increasingly mobile, and countries willing to invest in and respect that talent stand to gain not just prestige, but transformative discoveries.
In the case of cancer research — a field where time, talent, and tenacity are all critical — the loss of a mind like Dr. Feng’s could prove costly for a nation still battling to cure one of its deadliest diseases.
